Neurocrine Biosciences, Inc. (NBIX)

NASDAQ: NBIX · IEX Real-Time Price · USD
136.87
-0.97 (-0.70%)
Mar 28, 2024, 1:34 PM EDT - Market open

Company Description

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally.

The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications.

The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL " Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Neurocrine Biosciences, Inc.
Neurocrine Biosciences logo
Country United States
Founded 1992
IPO Date May 23, 1996
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 1,400
CEO Dr. Kevin C. Gorman Ph.D.

Contact Details

Address:
12780 El Camino Real
San Diego, California 92130
United States
Phone (858) 617-7600
Website neurocrine.com

Stock Details

Ticker Symbol NBIX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000914475
CUSIP Number 64125C109
ISIN Number US64125C1099
Employer ID 33-0525145
SIC Code 2836

Key Executives

Name Position
Dr. Kevin C. Gorman Ph.D. Chief Executive Officer and Director
Matthew C. Abernethy Chief Financial Officer
Darin M. Lippoldt Esq. Chief Legal Officer and Corporate Secretary
Kyle W. Gano Ph.D. Chief Business Development and Strategy Officer
Dr. Eiry Wyn Roberts M.D. Chief Medical Officer
Dr. Jude Onyia Ph.D. Chief Scientific Officer
Jane Sorensen Head of Investor Relations
Julie S. Cooke Chief Human Resources Officer
Eric S. Benevich Chief Commercial Officer
David Warren Boyer Chief Corporate Affairs Officer

Latest SEC Filings

Date Type Title
Mar 21, 2024 144 Filing
Mar 14, 2024 144 Filing
Mar 14, 2024 144 Filing
Mar 8, 2024 144 Filing
Mar 8, 2024 144 Filing
Feb 28, 2024 144 Filing
Feb 28, 2024 144 Filing
Feb 27, 2024 144 Filing
Feb 20, 2024 144 Filing
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals